1 . China's Volume-Based Procurement pricing policy continued to compress performance for multinational players with meaningful China exposure. Siemens Healthineers (-10.3% China), QuidelOrtho (-23% China), and Sysmex (-33.8% China local currency) all reported steep China declines that mask genuinely healthy performance outside the region.

2. Regulatory and clinical endorsements are becoming real competitive moats, not just marketing claims. The American Cancer Society's May 2026 reaffirmation of Cologuard as a preferred colorectal cancer screening option, Roche's first-to-market VENTANA companion diagnostics status, and Waters' FDA clearance of BACTEC FXI all convert clinical credibility directly into commercial defensibility.

3. Specialty Diagnostics saw the most consequential structural movement of any segment. Thermo Fisher's pending microbiology divestiture, Roche's $750M acquisition of PathAI, and Sysmex's newly closed BioMajesty chemistry acquisition all signal that portfolio boundaries across IVD are being actively redrawn

Q2 2026 IVD Performance Scorecard

Strategic-position tiers across four pillars: Revenue Growth, Innovation, M&A Activity, and Market Sentiment. Each company is scored by IVD business unit, so a company active in more than one segment appears once per segment below, reflecting that division's own performance.

Core Lab: Automation Leaders Pull Away as China Pressure Mounts

Core Lab in Q2 is a study in polarization. Automation investment and disciplined commercial execution are compounding into real competitive advantage for some players, while China pricing pressure and platform uncertainty are accelerating structural difficulty for others.

Core Lab Scorecard

LEADER · RESILIENT · UNDER PRESSURE · RESTRUCTURING. Tiers reflect this division only; a company scored differently in another segment reflects that division's own performance. All figures in USD.

Siemens Healthineers: A Carve-Out Enters Active Preparation

Siemens Healthineers reported Q3 FY2026 (calendar Q2 2026) global Diagnostics revenue of $1.1B, a -5.5% comparable decline, including a -10.3% comparable decline in China specifically. Atellica placements continued, but were offset by legacy system retirements diluting reagent pull-through, while ongoing healthcare procurement price standardization in China continued to delay purchasing decisions.

Siemens Healthineers is advancing preparations for a formal carve-out of its Diagnostics division, creating organizational uncertainty during the transition. The carve-out process opens a real displacement window for competitors targeting expiring Atellica contracts while lab directors weigh Siemens' long-term diagnostics roadmap.

“For fiscal year 2026, we now expect comparable revenue growth between 3.5% and 4.0% over fiscal year 2025 (previously between 4.5% and 5.0%), primarily as a result of the performance of the Diagnostics segment.”

(Siemens Healthineers Earnings Release)

Abbott: Alinity's Installed Base Keeps Compounding

Abbott's worldwide Core Laboratory Diagnostics sales reached $1.4B in Q2 2026, up 3.2% on a comparable basis, with U.S. Core Lab accelerating to +7.5% comparable growth. Growth was propelled by robust hospital chemistry and immunoassay testing across the U.S. and Latin America, alongside continued high-throughput Alinity placement momentum.

“Our test volume data, that's sourced directly from our diagnostic instruments located across the United States and around the world, continues to reflect strong and stable demand for testing.”

(Robert B. Ford, Chairman and CEO)

Sysmex: Hematology Leadership Backed by a Newly Closed Acquisition

Sysmex reported global Diagnostics revenue of $814.2M in Q1 FY2027 (calendar Q2 2026), up 12.7% on a constant-currency basis. Regional performance was led by the Americas ($263.3M, +26.1% local currency) and EMEA ($257.1M, +11.0%), while China ($84.0M) declined 33.8% in local currency and Japan ($109.2M) grew 57.9% on a yen basis.

Americas outperformance was driven by next-generation XN-Series hematology installs and strong Brazil hemostasis growth. Japan sales were boosted by JEOL's BioMajesty clinical chemistry business, which closed as a Sysmex acquisition on April 1, 2026. The combination of rapid hematology and hemostasis installations with the newly integrated chemistry business establishes a highly competitive Core Lab portfolio, one that presents a direct market-share threat to Beckman Coulter and Abbott's hospital footprints.

“In the hematology field in North America, the installation and start-up of instruments for orders previously received progressed smoothly, resulting in sales growth above our expectations.”

(Sysmex Q1 Q&A Summary)

Roche: China Drag Masking Ex-China Strength

Roche's Core Lab sales reached $2.2B in Q2 2026. On an H1 2026 basis, Core Lab CER growth was +4.0%, or +8.0% excluding the impact of China's healthcare pricing reform. Growth was led by immunodiagnostics and clinical chemistry assays, particularly infectious disease and bone health menus, with high-margin specialty menus cushioning Roche against China VBP headwinds.

“Sales in our largest franchise, the Core Lab, increased at 4%… excluding this effect, the Core Lab grew at 8%.”

(Matt Sause, CEO of Roche Diagnostics)

QuidelOrtho: China Uncertainty Weighs on an Otherwise Stable Base

QuidelOrtho's Labs revenue reached $382.9M in Q2 2026 (+2.4%), with Immunohematology at $134.2M (+0.7%); total Diagnostics segment sales were $631M, up 2.0% on a constant-currency basis. Absent national VBP pricing guidelines, China customers are delaying purchases and drawing down inventory, though ex-China performance remains solid, with Labs up 9.0% and Immunohematology up 5.0%.

QuidelOrtho's high China VBP exposure has forced a defensive commercial posture across its mature immunodiagnostics and blood-banking accounts, and the company cut full-year revenue guidance to $2.52B–$2.60B on continued China uncertainty.

“Uncertainty related to the proposed IVD pricing guidelines has impacted buying behavior as customers reduce their inventories pending the issuance of the final nationwide guidelines.”

(Brian Blaser, CEO)

Molecular Dx: Syndromic Point-of-Care and Oncology Moats Take Center Stage

Molecular diagnostics in Q2 was less about a single respiratory storyline and more about which platforms are converting clinical differentiation into durable competitive barriers.

Molecular Dx Scorecard

LEADER · RESILIENT · UNDER PRESSURE · RESTRUCTURING. Tiers reflect this division only; a company scored differently in another segment reflects that division's own performance. All figures in USD.

bioMérieux: SPOTFIRE's Growth Is Becoming Structural

bioMérieux's Molecular Biology revenue reached $415M in Q2 2026 (+2.5% organic growth), with the SPOTFIRE platform delivering $37M (+37.7% organic growth) and reagent sales up 40.0%. SPOTFIRE's installed base exceeded 7,200 units, with 400 new placements in Q2 alone, capturing share in decentralized urgent care settings and cushioning bioMérieux against a 6.0% decline in BIOFIRE respiratory panels, even as non-respiratory panels grew 7.0%.

bioMérieux's first-to-market syndromic point-of-care expansion lets urgent care clinics run a 20-minute multi-pathogen test, bypassing traditional central lab molecular delays. Both the FDA submission of the SPOTFIRE vaginitis panel and the CE marking of the first SPINCHIP assay landed in Q2

“With regards to SPOTFIRE, very strong performance… we've grown 40% in the context of low epidemiology, and 400 instruments installed in Q2 with no specific one-off.”

(Pierre Boulud, CEO)

Abbott: Cologuard's Growth Compounds Into a Clinical Endorsement Advantage

Abbott's Cancer Diagnostics revenue reached $0.9B in Q2 2026, up 13.3% on a comparable basis, while Rapid & Molecular Diagnostics revenue was $0.8B, an organic decline of 8.0% on lower seasonal respiratory testing volumes. Cologuard's mid-teens user growth, on a growing base of both new and repeat users, drove the Cancer Diagnostics result, and in May the American Cancer Society reaffirmed Cologuard and Cologuard Plus as preferred colorectal cancer screening options.

Abbott's integration of Exact Sciences is building a dominant colorectal screening moat at the primary-care level, one that makes it difficult for pure-play molecular labs to compete on screening economics alone.

“In cancer diagnostics, sales growth of 13% was driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users.”

(Robert B. Ford, Chairman and CEO)

Cepheid (Danaher): Diversifying Beyond Respiratory

Cepheid's Q2 2026 non-respiratory revenue grew in the low double-digits organically, led by sexual health and hospital-acquired infection (HAI) assays on the GeneXpert system. A new Multiplex GI panel launch and several large hospital network account wins reinforced this menu-driven growth, offsetting expected post-pandemic respiratory testing declines.

Cepheid is converting COVID-only GeneXpert instruments into stable, high-margin clinical portfolios, and a next-generation high-plex syndromic platform now in development represents a direct competitive threat to bioMérieux's BIOFIRE franchise.

“In molecular diagnostics, Cepheid's core non-respiratory revenue increased low double digits, led by growth in hospital-acquired infection and sexual health assays.”

(Rainer M. Blair, CEO)

Roche Molecular Lab: Transplant Testing Anchors a Defensive Menu

Roche's Molecular Lab sales reached $688.0M in Q2 2026, with H1 2026 CER growth of +3.0%, driven by 18.0% growth in transplant molecular testing. That non-respiratory specialty growth offset declines in respiratory testing and the cobas Liat near-patient system. Roche also reaffirmed its target of launching the Elecsys Interferon Gamma Release Assay for latent tuberculosis detection, further expanding its molecular screening menu.

“Sales in the Molecular Lab grew at +3% with, and I would call it the strong performance of our transplant business, which grew 18%.”

(Matt Sause, CEO of Roche Diagnostics)

Microbiology / Specialty Dx: Sepsis Speed Wars and Portfolio Realignment

No segment saw more structural movement in Q2 than Microbiology and Specialty Diagnostics. A major FDA clearance, a $750M acquisition, and a significant divestiture all landed within the same quarter.

Microbiology / Specialty Scorecard

LEADER · RESILIENT · UNDER PRESSURE · RESTRUCTURING. Tiers reflect this division only; a company scored differently in another segment reflects that division's own performance. All figures in USD.

Waters: BACTEC FXI Clearance Sets Up a Major Displacement Opportunity

Waters' Advanced Diagnostics Division (ADx) generated $521M in Q2 2026, up 7.0% organically, with acquired BDS delivering $449M (+5.0%) and the Clinical Business Unit (Mass Spec) delivering $72M (+14.0% constant currency). Early cost and revenue synergies from the BDS integration accelerated growth sequentially, and active pricing discipline drove a meaningful pricing lift.

The FDA-cleared BD BACTEC FXI blood culture system gives Waters an immediate advantage in sepsis diagnostics, with a 3-hour faster time-to-detection than incumbent platforms; it had already launched in Japan and Europe ahead of the U.S. clearance. With 4,500 U.S. instruments awaiting replacement, Waters has a large, well-defined displacement target directly threatening bioMérieux's blood culture base.

“With these businesses [BDS] under our leadership for the entirety of the quarter, we achieved a 400 basis point improvement in growth versus last quarter's flat full quarter growth rate.”

(Udit Batra, CEO)

Roche Diagnostics: A $750M Bet on Digital Pathology

Roche's Pathology Lab sales reached $501.0M in Q2 2026, with H1 2026 CER growth of +11.0%, led by advanced staining and companion diagnostics. Advanced staining grew 9% and companion diagnostics grew 23% in Q1, as precision oncology therapeutic approvals continue to drive mandatory companion testing; VENTANA holds first-to-market companion diagnostics status through Roche's pharmaceutical co-development relationships.

Roche's Pathology Lab franchise is heavily insulated from molecular respiratory seasonality and central lab price wars. The $750M acquisition of PathAI, announced May 6 with up to $300M in additional milestones, creates a digital-clinical pathology barrier that pushes competitors toward basic anatomical staining rather than high-value companion diagnostics.

“VENTANA advanced staining grew at +9% and companion diagnostics grew +23% in the first quarter, representing strong underlying demand as companion diagnostics are increasingly integrated with targeted therapeutics.”

(Matt Sause, CEO of Roche Diagnostics)

Thermo Fisher: Sharpening Focus Through a Microbiology Exit

Thermo Fisher's Specialty Diagnostics revenue grew 6.0% in Q2 2026 (organic growth of 5.0%), led by the healthcare market channel, transplant diagnostics, and immunodiagnostics. The company announced a pending microbiology divestiture, expected to close in Q3 2026, to sharpen focus on core specialty testing.

The strategic exit from clinical microbiology lets Thermo Fisher fully optimize its Specialty Diagnostics portfolio around the healthcare channel and transplant testing, a focused positioning expected to create pricing pressure in transplant diagnostics as competitors respond.

“Specialty Diagnostics grew 6% year-over-year, and organic revenue grew 5%. Growth in this segment was led by our healthcare market channel.”

(Thermo Fisher CFO)

bioMérieux Microbiology: Localization Defends Share in China

bioMérieux's global Microbiology revenue reached $365M in Q2 2026, up 6.5% organically, on strong momentum in BACT/ALERT blood culture and VITEK REVEAL rapid antimicrobial susceptibility testing placements. bioMérieux has localized manufacturing of two BACT/ALERT systems and the VITEK Compact Pro in China, along with local blood culture bottle production, a strategy that maintains premium consumables positioning and is forcing global competitors to accelerate their own localization efforts.

“Microbiology, so overall, plus 4% in H1. And notably, very strong dynamic on BACT/ALERT… and the positive price increase that we are able to deliver.”

(Pierre Boulud, CEO)

Bruker: ELITechGroup Integration Ahead of Plan

Bruker's CALID group (mass spec and molecular diagnostics) posted Q2 2026 sales of $310.3M, up 8.6% versus Q2 2025's $285.8M, with 1H2026 CALID sales totaling $626.6M. The ELITechGroup molecular diagnostics integration is performing well ahead of business plan, placing high volumes of instruments and building a base for future consumables pull-through, while MALDI Biotyper platforms continue attracting strong interest for rapid bacterial identification.

“First half placements in molecular diagnostics, the ELITechGroup business was ahead, well ahead of business plan, and that bodes very well as the consumables pull through.”

(Frank Laukien, CEO)

Bio-Rad: QC Fortress Remains the Stabilizer

Bio-Rad's Clinical Diagnostics revenue reached $399.0M in Q2 2026 (+2.6% reported, +0.3% currency-neutral), with 1H2026 sales totaling $762.6M. Growth was led by quality systems (QC controls), diabetes monitoring (HbA1c), and blood typing, with strong Americas demand partially offset by a high-teens decline in China tied to quality control order timing. Bio-Rad's restructuring program, targeting $30M–$35M in annualized savings by late 2027, is a competitive cost-position signal worth tracking.

“Clinical Diagnostics returned to modest currency-neutral growth, led by quality controls in our blood typing portfolio.”

(Jon DiVincenzo, President and COO)

Qiagen: QuantiFERON Stabilizes, Digital PCR Scales

Qiagen's Diagnostic Solutions sales declined 2.0% CER in Q2 2026, while overall company revenue was flat at $535M (0.0% CER growth). QuantiFERON grew 1.0% CER, returning to growth as strong general clinical testing offset a sharp decrease in U.S. immigration testing volumes. QIAstat-Dx declined 7.0% CER against a tough respiratory comparison, though GI and meningitis panels grew, while QIAcuity digital PCR grew double-digits CER on clinical consumables demand.

“We achieved solid growth across key pillars, particularly Sample technologies, QIAcuity and QDI, while navigating continued pressure on instrument spending in the U.S.”

(Thierry Bernard, CEO)

What to Watch in Q3 2026

Several dynamics will determine whether Q2's underlying moat-building translates into visible performance improvement in Q3, or whether macro headwinds continue to distort the picture.

Molecular Dx

Work with Ensolve Research

Ensolve Research is a MedTech marketing research consultancy specializing in the IVD and medical technology industries. We design and execute primary research that translates market signals into actionable marketing & commercial intelligence.

Our 2026 IVD research capabilities include:

• Global VOC Studies — Structured interviews and surveys with lab directors, clinical scientists, and procurement leaders across US, EMEA, and APAC
• Pricing Research — Conjoint analysis, willingness-to-pay, and price elasticity studies for novel assay and platform launches
• Platform Displacement Research — Identifying the specific triggers that cause lab directors to switch platforms
• Sample Journey & Workflow Mapping — Ethnographic research into clinical diagnostic workflows to identify unmet needs
• Concept & Messaging Optimization — Pre-launch testing of clinical claims and value propositions with target buyer segments
• Competitive Wargaming — Structured research-based competitive positioning studies for platform launch strategy

If your team is evaluating a platform launch, menu expansion, or competitive displacement strategy in 2026, these questions are not theoretical — they are commercial decisions.

Ensolve Research designs VOC research to answer them before launch.